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CC BY-NC-ND license (http://creativeBackground/purpose: Identifying trends in the prevalence and incidence of Parkinson’s disease
(PD) may yield information that supports public health goals. Our aim was to evaluate time-
trend changes in the prevalence and incidence of PD in Taiwan between 2004 and 2011.
Methods: This retrospective, nationwide, longitudinal study used the Taiwan National Health
Insurance Research Database to identify patients with PD from 2004 to 2011 based on having
ICD-9-CM diagnostic codes, which were assigned by neurologists, and being prescribed PD
medication. Annual incidence and prevalence were calculated, and time-trend analyses were
estimated assuming a Poisson distribution.
Results: Over the study period, 19,302 patients in 2004 and 41,606 patients in 2011 fulfilling
the study criteria for PD were included in the analysis. The average age-standardized preva-
lence of PD per 100,000 of population was 84.8 in 2004 and 147.7 in 2011, with a 7.9% yearly
increase. Increasing prevalence trends of PD were statistically significant (p < 0.001) in all
age groups, with the steepest rate among those aged  80 years. In contrast, the average
age-standardized incidence of PD decreased steadily from 35.3 per 100,000 in 2005 to 28.8
per 100,000 in 2011. The incidence rate was higher in men than in women, and increased with
age.ave no conflicts of interest relevant to this article.
Chang, Department of Medicine, College of Medicine, National Taiwan University Hospital, No.7
aiwan.
Lin, Department of Neurology, National Taiwan University Hospital, No.7 Chung-Shan South Road,
hoo.com.tw (C.-H. Chang), chlin@ntu.edu.tw (C.-H. Lin).
5.05.014
an Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
532 W.-M. Liu et al.Conclusion: We identified an increasing trend in the annual prevalence rates of PD from 2004
to 2011; however, the substantial decline in the incidence of PD suggests that some major
environmental risk factors for PD were removed from this population during this time period.
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Parkinson’s disease (PD), a disorder of complex etiology
including both genetic and environmental factors, is one of
the most common neurodegenerative diseases.1 The past
decade has been characterized by a remarkable accelera-
tion in the identification of genetic variants linked to a
minority of PD cases;2 however, penetrance is often
incomplete. This observation suggests the importance of
environmental risk factors, including exposure to certain
agricultural chemicals that have also been associated with
an increased risk of PD.3
Given that the population worldwide has aged dramati-
cally in the past decade, the impact of PD on global society
is a major concern. A key to unravelling the etiology of PD is
to investigate its occurrence and distribution within com-
munities and globally. Time trends in the incidence and
prevalence of PD may help to generate new etiologic hy-
potheses and enable public health systems to project the
future burden of these disabling conditions and plan med-
ical services based on these projections.
Previous studies comparing prevalence rates across
different regions have had conflicting results.4e7 A recent
meta-analysis of prevalence studies reported a stable
prevalence rate in the UK in recent decades,8 and a similar
stable trend of the prevalence of PD was also observed in a
US county over a 15-year period.9 However, no population-
based large-scale analyses have been published on the
incidence and prevalence of PD over time in Asia. We
therefore conducted time-trend analyses of the prevalence
and incidence of PD in Taiwan from 2004 to 2011,
comparing the sexes and different age groups, and report
the findings in the context of previous results for Taiwan
and western countries.Methods
Data source
The Taiwanese government launched the National Health
Insurance (NHI) program in March 1995, which covered
>99% of the total population by the end of 2008.10 The NHI
Research Database was developed at the National Health
Research Institute, with linked data from demographic and
enrollment records, hospital claims, ambulatory care visits,
and pharmacy-dispensing claims from hospitals, outpatient
clinics, and community pharmacies. Every individual in
Taiwan has a unique personal identification number. Data
on patient identities are scrambled cryptographically bythe National Health Research Institutes to protect patient
privacy.
Our study was approved by the Research Ethics Com-
mittee of National Taiwan University Hospital. No informed
consent from participants was required because the data
were analyzed anonymously. We analyzed data from 2004
to 2011.
Study population
We searched the entire population in the Taiwan National
Health Insurance Database from 2004e2011 to identify any
outpatient visitor or hospitalized individual with PD as one
of the diagnoses (International Classification of Diseases,
9th Revision, Clinical Modification; ICD-9-CM code: 332.0).
Patients were classified as having PD and included in the
analysis if they had at least one hospital admission or one
neurologist outpatient visit using the PD diagnostic code,
and if they received PD medication (including levodopa,
carbidopa, bromocriptine mesylate, pergolide mesylate,
amantadine, anticholinergics, selegiline, cabergoline,
ropinirole, or pramipexole; Anatomical Therapeutic
Chemical Classification System, N04) in any of the calendar
years. To improve the diagnostic accuracy and to exclude
patients with possible secondary parkinsonism, patients
who had had a diagnosis of dementia, cerebrovascular
diseases, head trauma, or psychotic disorders at the time
of, or 1 year before the diagnosis of PD were excluded.
Incident and prevalent case ascertainment
An incident case was ascertained after confirming that the
patient met the criteria for PD in the claims database with a
minimum of 1 year. As a result, we could only identify
incident cases after 2005. The hospital admission date or
the first date of an outpatient visit that met our definition
of PD, whichever came first, was used as the date of the
incident event. Patients were classified as prevalent cases
if they met the criteria for PD in each year of the study, but
were not incident cases. Because no death records are in
the database, we assumed that patients with PD had an
unknown vital status if there was no claim for any health
service in the database for >1 year, and they were not
counted as prevalent cases after the date of the last
record.
Statistical analysis
We calculated the annual incidence and prevalence of PD
from 2004 to 2011 by dividing the number of patients by the
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fidence intervals were not calculated because we analyzed
data from the whole nation without sampling. The age- and
gender-specific annual estimates were calculated for
groups aged < 50 years, 50e59 years, 60e69 years, 70e79
years, and  80 years. Age-adjusted, sex-specific estimates
were directly standardized by applying the age-specific
rates to those of the population in 2005. Results are further
presented as graphs stratified by sex and age. Poisson
regression adjusted by age was used to analyze each year’s
trend of the prevalence and incidence of PD. Calendar year,
as the continuous variable, was used in the model for linear
trend, and an interaction term with sex cross-product year
was used to test the difference in trends between men and
women. For results indicating significant trends in each
year, the percent change in incidence and prevalence atFigure 1 Time trends in the average prevalence (prevalent case
age between 2004 and 2011.the end of the study period (2011) was compared to that at
the beginning of the study (2004).Results
A total of 19,302 patients in 2004 and 41,606 patients in
2011 fulfilled study criteria for PD and were included in the
analysis. The average age-standardized prevalence of PD
per 100,000 of population was 84.8 in 2004 and 147.7 in
2011, accounting for a 7.9% increase each year. Figure 1A
shows that the annual standardized prevalence steadily
increased for both men and women during the study period.
Table 1 summarizes the age- and sex-specific annual prev-
alence of PD. A higher annual prevalence was observed in
the older age groups in both men and women, with as per 100,000 people) of Parkinson’s disease by (A) sex and (B)
Table 1 Prevalence of Parkinson’s disease in Taiwan from 2004 to 2011 (per 100,000 of population).
Year 2004 2005 2006 2007 2008 2009 2010 2011 p
Prevalent cases 19,302 23,875 27,604 31,176 33,904 36,618 39,256 41,606
Crude prevalence rate 84.8 104.9 120.7 135.8 147.2 158.4 169.5 179.1
Standardized prevalence rate 84.8 104.8 117.7 128.9 135.5 140.9 145.1 147.7 < 0.001
Age group (y)
50e59 63.0 73.8 79.5 86.5 90.7 93.5 94.8 96.8 < 0.001
60e69 303.3 360.5 392.8 417.9 426.6 432.3 429.5 410.4 < 0.001
70e79 814.6 1007.5 1142.1 1235.1 1300.8 1347.3 1379.5 1406.0 < 0.001
80 857.8 1145.4 1342.1 1562.4 1690.4 1809.8 1953.6 2076.6 < 0.001
Sex
Men 87.1 106.6 120.0 131.7 138.1 143.7 147.5 149.7 < 0.001
Women 82.3 103.1 115.2 126.1 132.9 138.2 142.6 145.6 < 0.001
534 W.-M. Liu et al.slightly higher prevalence in men. Although all increasing
trends for prevalence of PD were statistically significant in
each age group (p < 0.001), the highest increasing rate was
observed in those aged  80 years (Figure 1B). From 2004 to
2011, the annual prevalence increased in that group by
19.5% (from 1932.6 to 2207.0 per 100,000) among men and
by 21.3% (from 783.0 to 1948.0 per 100,000) among women,
followed by a 9.62% increase (from 829.1 to 1387.3 per
100,000) among men and 11.1% increase (from 799.2 to
1421.9 per 100,000) among women in the 70e79-year age
group; by 4.8% (from 309.6 to 414.3 per 100,000) among
men and 5.3% (from 297.4 to 406.7 per 100,000) among
women in the 60e69-year age group; and by 8.2%
(from 67.3 to 105.9 per 100,000) among men and 7.1% (from
58.7 to 87.9 per 100,000) among women in the 50e59-year
age group.
The number of annual incident cases of PD decreased
from 8297 in 2005 to 8031 in 2011. We found that the
average age-standardized incidence rate of PD per 100,000
decreased from 35.3 in 2005 to 28.8 in 2011. Table 2 sum-
marizes age- and sex-specific annual incidence rates of PD,
showing that higher incidence rates were observed in older
age groups in both men and women, with a slightly higher
incidence in men, especially those aged  80 years; how-
ever, women aged 60e69 years had a higher incidence
compared with men. As depicted in Figure 2A, in contrast
with the increasing trends for prevalence, a significant
decrease in the incidence rate of PD was observed for both
men and women. The most obvious tendency for decreasingTable 2 Incidence of Parkinson’s disease in Taiwan from 2005
Year 2004 2005 2006
Incident cases
Crude incidence rate d 35.3 33.6
Standardized incidence rate d 35.3 32.7
Age group (y)
50e59 d 22.7 21.3
60e69 d 119.2 104.7
70e79 d 338.3 318.7
80 d 402.0 385.9
Sex
Men d 35.3 33.2
Women d 35.3 32.2incidence was in the 60e69-year age group in both sexes
(4.5% for men and 5.0% for women).Discussion
To the best of our knowledge, this is the first study to
assess the time trends of PD incidence and prevalence in an
Asian population. We found an increased trend in the age-/
sex-standardized annual prevalence rates of PD over the
past 8 years. The prevalence was slightly higher in men
than in women and increased steadily with age. Notably,
our results showed that the incidence of PD decreased
gradually throughout the study period, although the inci-
dence rate was higher in men than in women and increased
with age.
We observed a gradual increase in PD prevalence
throughout the study period. Similar results have also been
reported for Japan, Israel, and France in the past decade
(Figure 3A).11e13 Although our prevalence rate was lower
than those in Israel and France,12,13 it was comparable with
that of Japan.11 Both changes over time in the incidence of
PD and the length of survival of individuals with PD affect
the prevalence of PD. Because the incidence rate showed a
decreased trend, we speculate that the increasing preva-
lence of PD over time may come from an increase in the
general aging population in Taiwan.14 Taiwan has become
an aging society since 1993, when the percentage of the
population aged > 65 years reached 7% and increasedto 2011 (per 100,000 of population).
2007 2008 2009 2010 2011 p
33.9 32.6 33.4 34.4 34.7
32.2 30.1 29.8 29.6 28.8 < 0.001
21.5 20.9 20.8 20.4 19.8 0.006
105.4 97.0 95.6 89.8 85.1 < 0.001
305.2 292.6 288.8 285.0 275.2 < 0.001
382.3 344.3 345.6 365.2 364.1 < 0.001
33.1 30.3 30.4 30.0 29.2 < 0.001
31.2 29.8 29.3 29.3 28.3 < 0.001
Figure 2 Time trends in the average incidence (new cases per 100,000 people) of Parkinson’s disease by (A) sex and (B) age
between 2004 and 2011.
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and Wales showed decreasing mortality rates from PD in
both men and women from 1993 to 2006, largely because of
improvements in treatments for PD and general medical
care.15,16
Our results suggest the multidisciplinary approach to
managing patients with PD, combining pharmacological
treatment with non-pharmacological interventions which
has proven beneficial in recent years, has been success-
ful.17 The findings also show that the prevalence of PD in-
creases with age, and steeply increases after 60 years of
age (Figure 1B), which is compatible with the fact that PD is
a progressive, disabling, neurodegenerative disordercharacterized by the degeneration of dopaminergic neurons
in the substantia nigra of the brain.18
Additionally, our data were consistent with findings from
previous studies conducted in rural areas of Taiwan, Kin-
men, and Ilan; studies from North America/Europe; and one
recent study from China (Table 3). An exception is the
70e79-year age group, which had a higher prevalence in
our study compared with previous findings. Our national
trends are, however, comparatively lower than those re-
ported for an urban city in Taiwan.4 We hypothesize that
the convenience of medical access and higher socioeco-
nomic status, along with better drug adherence in urban
areas, may partly explain these urbanerural differences in
PD prevalence.19 These observations suggest a distribution
Figure 3 Comparison of the time-trend changes in the average age-specific (A) prevalence and (B) incidence rates of PD between
Taiwan, France 12, Israel 13 and the UK 8.
536 W.-M. Liu et al.heterogeneity of PD, even though the genetic background is
similar, and further emphasize the importance of nation-
wide study designs, as in the current work.
In contrast with the findings of an increased trend in
the prevalence of PD, we observed a decreased trend in
the incidence of PD. Similar trends have been reported in
the UK between 1999 and 2009 (Figure 3B), although the
average annual incidence rate was higher than in ourpopulation (84 per 100,000/y vs. 31 per 100,000/y).15
There was a downward trend in the incidence of PD in
the UK study, with adjusted incidence rates declining by
approximately 6% every calendar year during the study
period.15 Previous studies of time trends of the incidence
of PD in Olmsted County in the US, however, suggested a
stable trend in the incidence of PD between 1976
and 1990.9 Studies conducted in France (2005 and 2010)12
Table 3 Comparison of the prevalence of Parkinson’s disease by local geographic regions within Taiwan and China (per
100,000 of population).
Geographic regions <50 y 50e59 y 60e69 y 70e79 y 80 y
Rural areas in Taiwan
Kinmen6 NA 273 535 565 1839
Ilan5 38 123 547 820 2198
Urban areas in Taiwan
Keelung4 NA 121 687 1838 4328
Nationwide study in Taiwan
Current study (2011) 20 (CI) 97 (CI) 410 (CI) 1406 (CI) 2077 (CI)
China28 NA 133 422 825 1663
Other Asian countries22 NA 88 (39e201) 376 (166e848) 646 (320e1345) 1418 (612e3285)
North America/Europe29 NA 113 (49e261) 540 (373e781) 1602 (1219e2105) 2953 (1936e4503)
CI Z confidence interval; NA Z not applicable.
Prevalence and incidence of Parkinson’s disease 537and Israel (1998 and 2008)13 using a database study
design also demonstrated relatively stable trends in the
incidence of PD in recent decades (Figure 3B), although
the incidence rate was comparable to that identified in
our study.
We hypothesize that because the genetic background of
our population did not change much over the past decade,
the most probable reason for the decreasing incidence rate
of PD may be lifestyle changes due to urbanization and
industrialization of society during this time period. 19e21
Lifestyle changes, with more tap water use rather than
well water, working environment changes with a decreased
population working in agriculture, and dietary changes,
with an increased consumption of caffeine-containing
drinks, could all potentially contribute to this decreasing
trend in the incidence of PD in our population.20,22
Not surprisingly, our results showed a sex difference in
PD incidence rates, with more new cases in men than
women. Our findings are consistent with previous studies
and a recent systematic review.23e25 Possible reasons for
this divergence between men and women include the
neuroprotective effects of estrogen, a higher frequency of
exposure to toxins and minor head trauma in men, and
recessive susceptibility genes on the X chromosome.23,24
Our study has the following strengths. Firstly, we used
nationwide data and had a large sample size, which em-
phasizes the prevalence and incidence trends over an 8-
year time period. We used a strict definition to define pa-
tients diagnosed with PD (ICD-9 332.0 diagnosed by neu-
rologists and at least one PD treatment agent taken at the
same time), which made the statistical analysis more ac-
curate and reliable. Secondly, the NHI program in Taiwan
provides continuing universal coverage for the entire pop-
ulation in Taiwan, which avoids selection bias. Thirdly, NHI
datasets were used, which eliminated the need to minimize
the number of partients in the cohorts lost to follow up.
Finally, a large sample of geographically-dispersed patients
was easily obtained, which avoided regional differences in
estimations. However, our study also has some limitations.
The major limitation was that despite analyzing healthcare
records from a representative, national dataset, our diag-
nosis of PD was based on the diagnostic code from the NHI
database; therefore, we could not distinguish between
primary and secondary parkinsonism. However, weexcluded patients who had ever had diagnoses of dementia,
cerebrovascular diseases, head trauma, or psychotic dis-
orders at the time of, or 1 year before, the diagnosis of PD,
to exclude the possibility of enrolling patients with diffuse
Lewy body disease, vascular parkinsonism, and secondary
parkinsonism related to intracranial hemorrhage or neuro-
leptic use. We were unable to review the medical records
of all defined PD patients because all the medical infor-
mation from the national NHI database was de-identified
due to ethical requirements. Therefore, we had no clinical
data regarding neuroimaging examinations or the duration
of and treatment response to PD medications in the defined
PD patients, which hampered our ability to perform a
nationwide validation study. Therefore, to evaluate the
accuracy of the diagnostic criteria for PD in our study, we
performed a hospital-based validation study using the
medical records of patients who were consecutively diag-
nosed with PD from 2002 to 2010 and who received long-
term follow up at National Taiwan University Hospital, a
tertiary referral center in Taiwan. A movement disorder
specialist (CHL) evaluated the medical records of these
patients. PD was clinically diagnosed according to the
United Kingdom Brain Bank criteria.26 A total of 1985 PD
patients were confirmed by critical medical record review.
Among these clinically confirmed patients, 1883 (94.8%)
were identified using the diagnostic criteria in the main
study (based on ICD-9-CM code and medication history),
suggesting that the diagnostic sensitivity of our study
criteria is acceptable.27 Because prospective incidence
studies of PD are difficult and costly to perform and, thus,
many have important limitations,28,29 the analysis of this
database allowed us to examine a very large sample of
population-based information, reflecting clinical practice
in Taiwan over 8 years, and to study the results over time.
Additionally, because the death record is not included in
the National Health Research Institute database, we
assigned an unknown vital status to patients for whom
there was no claim for any health service in the database
for >1 year. We may have underestimated the actual death
rate in 2011 and therefore may have overestimated the
prevalence of PD in 2011.
The results of our study show temporal trends in the
incidence and prevalence of PD in Taiwan over the past 8
years. An accurate estimate of the disease burden is a
538 W.-M. Liu et al.necessary first step in efforts to mitigate the effects of a
projected wave of PD on public health economies. Future
longer-term follow-up studies examining genetic or envi-
ronmental exposures, individual characteristics (e.g.,
smoking), and carefully established PD diagnoses are
required for a better understanding of the relationship
between environmental and genetic risk factors for PD and
to guide future planning for resources and community costs
of this disease.
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